2Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care, 2003;26(3):881.
3Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes, 1999;48(1):99.
4Hu S, Wang S, Fanelli B, et al. Pancreatic β-cell KATP channel activity and membrane binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther, 2000; 293 (2): 444.
5Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care, 2001 ; 24 (1): 73.
6Hansen AM, Christensen IT, Hansen JB, et al. Differential interactions of nateglinide and repaglinide on the human betacell sulphonylurea receptor 1. Diabetes, 2002;51 (9): 2789.
7Kahn SE, Montgomery B, Howell WM, et al. Nateglinide increases first phase insulin secretion and enhances glucose clearance in type 2 diabetes. Diabetes, 2000; 49 (Suppl 1):A113.
8Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2001 ;86 (12) :5824.
9Raskin P, Klaff L, McGill J, et al. Repaglinide vs.Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care, 2003;26(7):2063.
10Rosenstock J, Shen SG, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care, 2002;25(9):1529.
